Want to see MCK full AI Analyst Report?
MCK Stock Chart & Stats
$905.09
$16.41(1.99%)
At close: 4:00 PM EDT
$905.09
$16.41(1.99%)
Day’s Range― - ―
52-Week Range$682.35 - $999.00
Previous CloseN/A
Volume823.78K
Average Volume (3M)992.38K
Market Cap
$105.72B
Enterprise Value$99.45K
Total Cash (Recent Filing)$5.16B
Total Debt (Recent Filing)$11.70B
Price to Earnings (P/E)24.6
Beta0.21
Next Earnings
Nov 03, 2026EPS Estimate
10.72Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)37.53
Shares Outstanding116,590,360
10 Day Avg. Volume933,487
30 Day Avg. Volume992,380
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio19.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$987.75Price Target Upside9.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)44.62
Revenue Forecast (FY)$431.96B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent conversion of earnings into substantial operating and free cash flow supports debt service, reinvestment, acquisitions and shareholder returns. This provides resilience for a low-margin distribution model and helps fund strategic initiatives internally.
Broad-based Earnings GrowthRaised guidance indicates management sees durable momentum across pharmaceuticals, oncology and prescription technology services. Growth in both revenue and operating profit suggests scale, volume expansion and operating leverage can support earnings over the next several quarters.
Oncology Platform ExpansionThe acquisition broadens McKesson’s oncology and multispecialty capabilities beyond distribution into clinical research and commercialization services. These complementary offerings may deepen customer relationships, diversify revenue and reinforce exposure to specialty-care growth.
Bears Say
Persistently Negative EquityNegative equity reduces financial flexibility and makes conventional leverage signals harder to interpret. Although debt is moderate relative to scale, a thinner balance-sheet cushion could constrain options or increase downside sensitivity during operational or regulatory stress.
Thin And Pressured MarginsVery low margins leave earnings sensitive to purchasing terms, customer pricing, product mix and cost inflation. The multi-year gross-margin decline suggests scale alone may not fully protect profitability if branded pricing, generic mix or competitive pressure worsens.
Transition And Policy PressureThe MedSurg decline and evolving drug-pricing policies create ongoing execution and reimbursement risks. These pressures can affect segment profitability, revenue comparisons and capital allocation, particularly while McKesson completes the MedSurg separation and adjusts to regulation.
McKesson News
MCK FAQ
What was Mckesson Corp.’s price range in the past 12 months?
Mckesson Corp. lowest stock price was $682.35 and its highest was $999.00 in the past 12 months.
What is Mckesson Corp.’s market cap?
Mckesson Corp.’s market cap is $105.72B.
When is Mckesson Corp.’s upcoming earnings report date?
Mckesson Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 61 days.
How were Mckesson Corp.’s earnings last quarter?
Mckesson Corp. released its earnings results on Aug 05, 2026. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.561 by $0.369.
Is Mckesson Corp. overvalued?
According to Wall Street analysts Mckesson Corp.’s price is currently Undervalued.
Does Mckesson Corp. pay dividends?
Mckesson Corp. pays a Quarterly dividend of $0.94 which represents an annual dividend yield of 0.37%. See more information on Mckesson Corp. dividends here
What is Mckesson Corp.’s EPS estimate?
Mckesson Corp.’s EPS estimate is 10.72.
How many shares outstanding does Mckesson Corp. have?
Mckesson Corp. has 116,590,360 shares outstanding.
What happened to Mckesson Corp.’s price movement after its last earnings report?
Mckesson Corp. reported an EPS of $9.93 in its last earnings report, beating expectations of $9.561. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of Mckesson Corp.?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$987.75 (9.13% Upside)
$987.75 (9.13% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 513.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $268.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.73%
12-Months-Change
Fundamentals
Return on Equity
0.37%
Trailing 12-Months
Asset Growth
8.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mckesson Corp.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: double-digit EPS growth, an 8% revenue increase to $105.4B, broad-based segment strength (notably Oncology & Multispecialty and North American Pharmaceuticals), improved gross profit and operating leverage, a raised full-year EPS guide, active capital returns (large buyback and dividend increase), and continued strategic progress on the MedSurg separation and tech/AI initiatives. Lowlights included a quarterly negative free cash flow readout (seasonal but improved vs prior year), a 20% decline in MedSurg operating profit, financing-related interest expense and GAAP remeasurement charges, and macro/regulatory uncertainties (WAC reductions, branded-to-generic conversions, 340B/IRA policy risks). Overall, the positive operational and financial beats and raised guidance materially outweigh the noted one-offs, financing costs, and policy risks.View all MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
$987.75
▲(9.13% Upside)
Technical Analysis
Cencora
―
Cardinal Health
―
Henry Schein
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
0.04% Insiders
24.14% Mutual Funds
13.32% Other Institutional Investors
39.11% Public Companies and
Individual Investors